 |
Publisher: Peytchinski Publishing Ltd.
ISSN: 1312-773X (Online)
Issue: 2021, vol. 27, issue4
Subject Area: Medicine
-
DOI: 10.5272/jimab.2021274.4170
Published online: 17 December 2021
Original article
J of IMAB. 2021 Oct-Dec;27(4):4170-4177
STUDY OF SERUM OSTEOPROTEGERIN AND RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA-Β LIGAND IN PATIENTS WITH RHEUMATIC DISEASES
Mariela Geneva-Popova
, Stanislava Popova,
Propaedeutics of Internal Diseases, Faculty of Medicine, Medical University - Plovdiv;
Rheumatology, UMHAT "Sveti Georgi" Plovdiv, Bulgaria.
ABSTRACT:
Although rheumatological diseases are widespread, they still have an unclear etiology, pathogenesis, and therapy. Researchers are looking for biomarkers associated with inflammatory and degenerative joint diseases. Serum Osteoprotegerin (s-OPG) and serum Receptor Activator of Nuclear Factor Kappa-Β Ligand (s-RANKL) have not been studied in patients with Diffuse idiopathic skeletal hyperostosis (DISH), spondylosis, ankylosing spondylitis, and gout.
The aim of this study was to investigate s-OPG and s-RANKL in patients with various rheumatic diseases.
Materials and methods: We studied 135 patients with rheumatic diseases, of which 55 were diagnosed with DISH, 50 with spondylosis, 23 with ankylosing spondylitis, 7 with gout, and 25 were a control group. s-OPG and s-RANKL, serum calcium, ionized calcium, serum phosphorus, alkaline phosphatase, uric acid, urea, creatine, and serum osteocalcin were tested using the ELISA method in the Clinical Laboratory of "St. George" University Hospital, Plovdiv. The results were processed using the statistical program SPSS ver 26, with significance p<0.05.
Results: Patients with DISH and ankylosing spondylitis had higher levels of s-OPG, s-RANKL, and s-OPG/s-RANKL ratio than the control group (p<0.05). The s-OPG/s-RANKL ratio in patients with spondylosis and gout was lower than in patients with DISH and ankylosing spondylitis (p<0.05). There are strong correlations between s-OPG, s-RANKL, and the biochemical parameters related to bone metabolism (serum calcium, ionized calcium, serum phosphorus, alkaline phosphatase, uric acid, urea, creatine, and serum osteocalcin)(p <0.05).
Conclusion: Our studies show that changes in bone metabolism are similar in patients with DISH and ankylosing spondylitis. Further research is needed to look for a common pathogenetic pathway linking degenerative and inflammatory rheumatic diseases of the axial skeleton.
Keywords: serum osteoprotegerin, s-RANKL, rheumatic diseases,
- Download FULL TEXT /PDF 608 KB/
Please cite this article as: Geneva-Popova M, Popova S. Study of serum Osteoprotegerin and Receptor Activator of Nuclear Factor Kappa-Β Ligand in patients with rheumatic diseases. J of IMAB. 2021 Oct-Dec;27(4):4170-4177. DOI: 10.5272/jimab.2021274.4170
Correspondence to: Mariela Genceva Geneva-Popova, Medical University – Plovdiv, Faculty of Medicine, Propaedeutics of Internal Diseases; Rheumatology, UMHAT “Sveti Georgi” Plovdiv, Bulgaria; E-mail: genevapopova@yahoo.com
REFERENCES:
1. Childs SG. Diffuse idiopathc skeletal hyperostosis: Forestier's Disease. Orthop Nurs. 2004 Nov-Dec;23(6):375-82. [PubMed]
2. Holgate RL, Steyn M. Diffuse idiopathic skeletal hyperostosis: Diagnostic, clinical, and paleopathological considerations. Clin Anat. 2016 Oct;29(7):870-7. [PubMed]
3. Eser P, Bonel H, Seitz M, Villiger PM, Aeberli D. Patients with diffuse idiopathic skeletal hyperostosis do not have increased peripheral bone mineral density and geometry. Rheumatology (Oxford). 2010 May;49(5):977-81. [PubMed]
4. Kuperus JS, Mohamed Hoesein FAA, de Jong PA, Verlaan JJ. Diffuse idiopathic skeletal hyperostosis: Etiology and clinical relevance. Best Pract Res Clin Rheumatol. 2020 Jun;34(3):101527. [PubMed]
5. Boyce BF, Xing L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther. 2007; 9 Suppl 1(Suppl 1):S1. [PubMed]
6. Pérez-Sayáns M, Somoza-Martín JM, Barros-Angueira F, Rey JM, García-García A. RANK/RANKL/OPG role in distraction osteogenesis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010 May;109(5):679-86. [PubMed]
7. Kalkan R, Altarda M, Tosun O. RANKL is a new Epigenetic Biomarker for the Vasomotor Symptom During Menopause. Balkan J Med Genet. 2020 Aug 26;23(1):51-56. [PubMed]
8. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, et al. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998 May 1;12(9):1260-8.[PubMed]
9. Tsukasaki M, Asano T, Muro R, Huynh NC, Komatsu N, Okamoto K, et al. OPG Production Matters Where it happened. Cell Rep. 2020 Sep 8;32(10):108124. [PubMed]
10. Deligiorgi MV, Panayiotidis MI, Griniatsos J, Trafalis DT. Harnessing the versatile role of OPG in bone oncology: counterbalancing RANKL and TRAIL signaling and beyond. Clin Exp Metastasis. 2020 Feb;37(1):13-30. [PubMed]
11. Harper E, Forde H, Davenport C, Rochfort KD, Smith D, Cummins PM. Vascular calcification in type-2 diabetes and cardiovascular disease: Integrative roles for OPG, RANKL and TRAIL. Vascul Pharmacol. 2016 Jul;82:30-40. [PubMed]
12. Silva I, Branco JC. Rank/Rankl/opg: literature review. Acta Reumatol Port. 2011 Jul-Sep;36(3):209-18. [PubMed]
13. Clézardin P. [The role of RANK/RANKL/osteoprotegerin (OPG) triad in cancer-induced bone diseases: physiopathology and clinical implications] [in French] Bull Cancer. 2011 Jul;98(7):837-46. [PubMed]
14. Stupphann D, Rauner M, Krenbek D, Patsch J, Pirker T, Muschitz C, et al. Intracellular and surface RANKL are differentially regulated in patients with ankylosing spondylitis. Rheumatol Int. 2008 Aug;28(10):987-93. [PubMed]
15. Nitta K, Akiba T, Uchida K, Kawashima A, Yumura W, Kabaya T, et al. The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis. Am J Kidney Dis. 2003 Aug;42(2):303-9. [PubMed]
16. Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab. 2001 Feb;86(2):631-7. [PubMed]
17. Harper E, Rochfort KD, Smith D, Cummins PM. RANKL treatment of vascular endothelial cells leading to paracrine pro-calcific signaling involves ROS production. Mol Cell Biochem. 2020 Jan;464(1-2):111-117. [PubMed]
18. Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest. 2003 Apr;111(8):1221-30. [PubMed]
19. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997 Apr 18;89(2):309-19. [PubMed]
20. Hermann KG, Bollow M. Rethinking diffuse idiopathic skeletal hyperostosis. Rheumatology (Oxford). 2014 Nov;53(11):1917-9. [PubMed]
21. Olmedo-Garzón FJ, Ruiz Ollero A. Diffuse Idiopathic Skeletal Hyperostosis and Ankylosing Spondylitis: Comment on the Article by Latourte et al. Arthritis Care Res (Hoboken). 2019 Aug;71(8):1148-1150.
22. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res. 2000 Jan;15(1):2-12. [PubMed]
23. Schett G, Kiechl S, Redlich K, Oberhollenzer F, Weger S, Egger G, et al. Soluble RANKL and risk of nontraumatic fracture. JAMA. 2004 Mar 3;291(9):1108-13. [PubMed]
24. Li CH, Ma ZZ, Jian LL, Wang XY, Sun L, Liu XY, et al. Iguratimod inhibits osteoclastogenesis by modulating the RANKL and TNF-α signaling pathways. Int Immunopharmacol. 2021 Jan;90:107219. [PubMed]
25. Qi D, Liu H, Sun X, Luo D, Zhu M, Tao T, et al. Pristimerin Suppresses RANKL-Induced Osteoclastogenesis and Ameliorates Ovariectomy-Induced Bone Loss. Front Pharmacol. 2021 Jan 15;11:621110. [PubMed]
26. Lian JB, Gundberg CM. Osteocalcin. Biochemical considerations and clinical applications. Clin Orthop Relat Res. 1988 Jan;(226):267-91. [PubMed]
27. Leibbrandt A, Penninger JM. RANKL/RANK as key factors for osteoclast development and bone loss in arthropathies. Adv Exp Med Biol. 2009;649:100-13. [PubMed]
28. Kalichman L, Kobyliansky E. Radiographic hand osteoarthritis and serum levels of osteocalcin: cross-sectional study. Rheumatol Int. 2010 Jun;30(8):1131-5. [PubMed]
29. Smith C, Voisin S, Al Saedi A, Phu S, Brennan-Speranza T, Parker L, et al. osteocalcin and its forms across the lifespan in adult men. Bone. 2020 Jan;130:115085. [PubMed]
30. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology. 2001 Dec;142(12):5050-5. [PubMed].
Received: 19 May 2021
Published online: 17 December 2021